Canada
· Delayed Price · Currency is CAD BriaCell Therapeutics Statistics
Total Valuation
TSX:BCT has a market cap or net worth of CAD 27.58 million. The enterprise value is 19.78 million.
| Market Cap | 27.58M |
| Enterprise Value | 19.78M |
Important Dates
The next estimated earnings date is Monday, June 9, 2025.
| Earnings Date | Jun 9, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TSX:BCT has 6.12 million shares outstanding. The number of shares has increased by 58.67% in one year.
| Current Share Class | 6.12M |
| Shares Outstanding | 6.12M |
| Shares Change (YoY) | +58.67% |
| Shares Change (QoQ) | +52.00% |
| Owned by Insiders (%) | 7.45% |
| Owned by Institutions (%) | 1.93% |
| Float | 5.12M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 5.91 |
| P/TBV Ratio | 5.59 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.18 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.61 |
Financial Position
The company has a current ratio of 1.37
| Current Ratio | 1.37 |
| Quick Ratio | 1.37 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -158.14% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -661.06% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -1.05M |
| Employee Count | 16 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -85.61% in the last 52 weeks. The beta is 1.80, so TSX:BCT's price volatility has been higher than the market average.
| Beta (5Y) | 1.80 |
| 52-Week Price Change | -85.61% |
| 50-Day Moving Average | 5.35 |
| 200-Day Moving Average | 10.76 |
| Relative Strength Index (RSI) | 44.16 |
| Average Volume (20 Days) | 13,801 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -39.54M |
| Pretax Income | -16.97M |
| Net Income | -16.78M |
| EBITDA | -39.35M |
| EBIT | -39.54M |
| Earnings Per Share (EPS) | -10.01 |
Balance Sheet
The company has 7.26 million in cash and n/a in debt, giving a net cash position of 7.26 million or 1.19 per share.
| Cash & Cash Equivalents | 7.26M |
| Total Debt | n/a |
| Net Cash | 7.26M |
| Net Cash Per Share | 1.19 |
| Equity (Book Value) | 4.67M |
| Book Value Per Share | 1.77 |
| Working Capital | 2.80M |
Cash Flow
In the last 12 months, operating cash flow was -31.83 million and capital expenditures -661,133, giving a free cash flow of -32.49 million.
| Operating Cash Flow | -31.83M |
| Capital Expenditures | -661,133 |
| Free Cash Flow | -32.49M |
| FCF Per Share | -5.31 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TSX:BCT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -58.67% |
| Shareholder Yield | n/a |
| Earnings Yield | -60.83% |
| FCF Yield | -117.82% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 29, 2025. It was a reverse split with a ratio of 0.0666667.
| Last Split Date | Jan 29, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.0666667 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |